Clinical trials: Type I Diabetes Mellitus
Diabetes Mellitus, Type 1
Evaluation of TTP399 in Patients With Type 1 Diabetes
The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1 diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different TTP399 dosage regimens over 1 week of daily dosing.
- Trial name
- SimpliciT1 (NCT03335371)
- Testing
- TTP399
- Where
- 15 sites in United States
- Volunteers
- 115 people
- Sponsor
- vTv Therapeutics
Type 1 Diabetes Mellitus
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
This Phase 2 study was intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and efficacy of sotagliflozin following daily oral administration for 29 days in participants with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT01742208
- Testing
- Sotagliflozin
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus
A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)
The purpose of Part I of this study is to evaluate the safety and tolerability of intravenous (IV) doses of MK-2640 in healthy participants and to obtain preliminary plasma pharmacokinetic profiles of MK-2640.
- Trial name
- NCT02269735
- Testing
- MK-2640, Regular Human Insulin (RHI), Dextrose
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes Mellitus
VV-14300 for the Treatment of Type 1 Diabetes
This study is testing VV-14300 in adults with long-standing type 1 diabetes (T1D) whose blood sugar is not well controlled despite using an automated insulin delivery (AID) system.
- Trial name
- RELIEVE (NCT07831798)
- Testing
- VV-14300
- Where
- 2 sites in Canada, New Zealand
- Volunteers
- 29 people
- Sponsor
- Kriya Therapeutics, Inc.
Diabetes Mellitus, Type 1
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
- Trial name
- CATT1 (NCT06334133)
- Testing
- Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- vTv Therapeutics
Chronic Kidney Diseases, Type 1 Diabetes Mellitus
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
The purpose of this study is to assess the safety, efficacy, and durability of up to two Renal Autologous Cell Therapy (REACT) / rilparencel injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys…
- Conditions
- Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- NCT05018416
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Prokidney
Type 2 Diabetes
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment
To evaluate the pharmacokinetic characteristics of pyroglutamate rongliflozin capsules in type 2 diabetic subjects with normal renal function and mild to moderate renal impairment.
- Trial name
- NCT05374343
- Testing
- pyroglutamate rongliflozin capsules
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Type 1 Diabetes Mellitus
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
This study will assess the safety and efficacy of secukinumab on the preservation of pancreatic beta cells in patients with newly-diagnosed type 1 diabetes mellitus.
- Trial name
- NCT02044848
- Testing
- Secukinumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring Systems
The purpose of the study is to evaluate the safety and effectiveness of the Abbott Sensor Based Glucose Monitoring System Personal (System-P) and Abbott Sensor Based Glucose Monitoring System Professional (System-Pro) when used…
- Trial name
- NCT02283411
- Testing
- Abbott Sensor Based Glucose Monitoring System
- Where
- 6 sites in United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Abbott Diabetes Care
Type II Diabetes Mellitus
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
The primary aim of this study is to evaluate the safety and tolerability of AZD1656 in T2DM patients treated with metformin and sulfonylurea.
- Trial name
- NCT00995787
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Neoantigen Cancer Vaccine
The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients…
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT03639714
- Testing
- GRT-C901, GRT-R902, nivolumab
- Where
- 11 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Gritstone bio, Inc.
Type 1 Diabetes Mellitus
To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.
- Trial name
- NCT01110746
- Testing
- Viaject 7, LISPRO
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Biodel
Type 2 Diabetes Mellitus
Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus
The purpose of this study is to determine whether administration of AZD1656 will affect the pharmacokinetics of Pioglitazone and vice versa in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01082120
- Testing
- AZD1656, Pioglitazone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes
The purpose of this study is to determine if oral Cyclosporine A and oral Lansoprazole are effective in rendering patients with existing type 1 diabetes, insulin independent.
- Trial name
- IIT (NCT01762657)
- Testing
- Oral Cyclosporine and Oral Lansoprazole
- Sponsor
- Perle Bioscience, Inc.
Diabetes Mellitus
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes
- Trial name
- NCT00287066
- Testing
- Inhaled Human Insulin, Regular Human Insulin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetic Gastroparesis
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered…
- Trial name
- DIGEST (NCT01664637)
- Testing
- 10 mg TZP-102
- Where
- 35 sites in United States, Poland
- Volunteers
- 120 people
- Sponsor
- Tranzyme, Inc.
Diabetes Type 1
Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France
This is a non-interventional, longitudinal, prospective, multicenter, post market-registration and national study conducted in France.
- Trial name
- EPICAM-G6 (NCT07048795)
- Testing
- No Intervention: Observational Cohort
- Where
- 22 sites in France
- Volunteers
- 125 people
- Sponsor
- mylife Diabetes Care AG
Hypertension
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure.
- Trial name
- NCT00403481
- Testing
- olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
- Where
- 27 sites in United States
- Volunteers
- 192 people
- Sponsor
- Daiichi Sankyo
Type 1 Diabetes Mellitus
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study. The goal of this Phase 2a study is to assess safety and efficacy of brivekimig in comparison to placebo to preserve β-cell…
- Trial name
- T1D OBTAIN (NCT06812988)
- Testing
- Brivekimig
- Where
- 24 sites in United States, Argentina and 6 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
Type 1 Diabetes, Type 2 Diabetes
A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes
The main purpose of this study is to determine whether combining meal, glucose and insulin data in a web-based system will improve management of type 1 (T1D) and type 2 diabetes (T2D). No study drug will be given.
- Trial name
- NCT04667182
- Testing
- Meal-Tagging App and Web-based Portal:, Fitness Tracker
- Where
- 2 sites in United States
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.